Coronary Circulatory Function Abnormalities in Insulin Resistance Insights From Positron Emission Tomography by Schelbert, Heinrich R.
P
i
a
t
(
v
p
a
c
a
m
v
u
(
y
r
n
e
t
d
a
f
t
c
u
f
F
o
C
b
Journal of the American College of Cardiology Vol. 53, No. 5, Suppl S, 2009
© 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00
PSTATE-OF-THE-ART PAPERS
Coronary Circulatory Function
Abnormalities in Insulin Resistance
Insights From Positron Emission Tomography
Heinrich R. Schelbert, MD, PHD
Los Angeles, California
Traditionally, assessment of coronary circulatory function has been complex, requiring invasive techniques, in-
cluding quantitative coronary angiography, intracoronary flow velocity probes, and pharmacologic stressor
agents. However, radiotracer-based techniques for noninvasive measurement of myocardial blood flow are
now available. Studies using these new techniques demonstrate that insulin resistance is associated with func-
tional disturbances of the coronary circulation. Conversely, insulin infusion improves coronary flow, even in the
setting of type 2 diabetes mellitus and coronary artery disease. (J Am Coll Cardiol 2009;53:S3–8) © 2009 by
the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.09.053t
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cre-diabetic states of insulin resistance (IR), including
mpaired glucose tolerance and the metabolic syndrome, are
ssociated with clustering of cardiovascular (CV) risk fac-
ors, placing patients at increased risk for coronary events
1). Endothelial function is considered a “biomarker of
ascular disease” (2) and represents a link between complex
henomena at the molecular level and vascular pathology of
therosclerosis (3). Functional alterations of the peripheral
irculation can readily and noninvasively be assessed. One
pproach employs high spatial resolution ultrasonography to
easure flow-mediated brachial artery dilation and flow
elocity changes in response to reactive hyperemia and
pstream intra-arterially administered vasodilator agents
2). A second approach employs venous impedance pleth-
smography to evaluate endothelium-related microvascular
esponses to intra-arterially administered vasoactive ago-
ists (2). Indeed, the presence of functional, mostly
ndothelium-related, alterations of the peripheral circula-
ion has been demonstrated in persons with mild, pre-
iabetic IR (4,5). However, while studies show that brachial
rtery responses are a surrogate marker for coronary arterial
unction, this correspondence does not necessarily extend to
he microcirculation (6). Thus, direct assessment of the
oronary artery circulation is necessary if we are to fully
nderstand the vascular biology of IR and its implications
or CV risk.
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er 29, 2008.Initial approaches to directly assessing coronary circula-
ory function involved invasive techniques, including quan-
itative angiography, intracoronary flow velocity probes, and
harmacologic stressor agents such as acetylcholine, papav-
rine, and adenosine (7). The high cost and invasiveness of
his approach limit its use, especially in apparently healthy
ersons with early abnormalities like mild IR. Therefore,
oronary function in pre-diabetic persons remained relatively
nderstudied. However, the development of radiotracer-
ased techniques for measurements of myocardial blood
ow offers noninvasive characterization of coronary circula-
ory function. The following text summarizes observations
ith this noninvasive, radiotracer-based study approach and
ritically examines the effects of IR on total integrated
oronary function, endothelium-related disturbances, and
he implications thereof.
ositron Emission Tomography
PET) in Noninvasive Measurement
f Coronary Circulatory Function
yocardial blood flow (in ml/min/g) can be accurately and
eproducibly measured with PET and radiotracers of blood
ow such as O-15 water, N-13 ammonia, and rubidium-82
8–11). The ultra-short physical half-life of these radiotrac-
rs, ranging from 90 s to 9.8 min, affords repeat flow
easurements during a single 1- to 2-h study session so that
ow responses to specific stimuli can be evaluated. The
hort physical half-life of the radiotracers, combined with
heir high-energy photons, yields relatively low radiation
urdens comparable to, or less than, those encountered with
linical stress-rest single-photon emission computed to-
ography (SPECT) myocardial perfusion imaging with
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thallium-201. The high speed
and quantitative image acquisi-
tion capability of PET are essen-
tial for this approach.
The study of coronary func-
tion typically entails flow mea-
surements initially in the basal
state at rest, during pharmaco-
logically induced hyperemia, and
during sympathetic stimulation
by cold pressor testing (CPT)
(12,13). Each intervention ex-
amines a specific component of
coronary circulatory function.
Adenosine- or dipyridamole-
stimulated hyperemia probes the
total integrated coronary vasodi-
ator capacity, depending on both vascular smooth muscle
nd endothelial function. Hyperemic flow responses are
ediated by maximum smooth muscle relaxation of pre-
rteriolar resistance vessels and are also modulated by
ndothelium. With normal endothelial function, increases
n flow velocity increase endothelial shear stress, prompting
elease of vasodilator substances that lead to an increase of
he epicardial conduit vessel diameter, thereby lowering the
esistance to high-velocity flows.
Flow responses to sympathetic stimulation with CPT are
more selective reflection of endothelium-related vascular
unction. Exposure to cold, as by hand immersion in ice
ater, prompts an increase in heart rate and blood pressure
nd, therefore, in cardiac work, which is accompanied by a
ommensurate rise in myocardial blood flow (in the absence
f a coronary stenosis). The flow increase is initiated by a
etabolically mediated dilation of the coronary resistance
Abbreviations
and Acronyms
BMI  body mass index
CPT  cold pressor testing
CV  cardiovascular
eNOS  endothelial nitric
oxide synthase
IR  insulin resistance
NO  nitric oxide
PET  positron emission
tomography
SPECT  single-photon
emission computed
tomography
T2DM  type 2 diabetes
mellitus
Figure 1 Adenosine- or Dipyridamole-Stimulated Hyperemic MB
Comparison of hyperemic myocardial blood flow (MBF) responses to cold pressor t
lated hyperemic MBF. (B) Summary of cold pressor-induced change in MBF (MBF
mellitus as compared with attenuation of the flow response (B, MBP) to cold pre
mellitus; DMHTN  diabetes mellitus and arterial hypertension; IGT  impairedessels and is modulated by a complex interaction between
ascular smooth muscle-related vasoconstrictive and
ndothelium-related vasodilatory forces. In this scenario,
ympathetic stimulation leads to an alpha-adrenergically
ediated constriction of the vascular smooth muscle which,
nder normal conditions, is appropriately offset by shear
tress-mediated and, possibly, receptor-mediated endothe-
ial release of vasodilators such as prostacycline and, espe-
ially, nitric oxide (NO). In instances of diminished NO
ioavailability because of endothelial dysfunction, vasocon-
trictor effects can no longer be adequately opposed and
oronary flow responses to CPT become attenuated, absent,
r paradoxical, (i.e., coronary flow declines) (13).
oronary Circulatory Function in States of IR
rior et al. (12) studied 120 Mexican-American patients
ith IR of increasing severity, ranging from normoglycemic
R (by hyperinsulinemic-euglycemic clamping) to impaired
lucose tolerance and type 2 diabetes mellitus (T2DM),
ith and without hypertension. Hyperemic myocardial flow
nd therefore total vasodilator capacity was reduced only in
atients with T2DM (Fig. 1) (12). Coronary vasodilator
unction was preserved in IR and impaired glucose toler-
nce, but flow responses to CPT were attenuated. The
ttenuation of flow response progressively worsened across
he spectrum of IR and became paradoxical (decreased) in
2DM with hypertension as the most severe form of IR.
hese findings indicate the presence of functional impair-
ent in the background of mild IR in pre-diabetes. The
unctional disturbance is initially confined to endothelium-
elated vasomotion, increases in severity with more severe
tates of IR, and eventually compromises total vasodilator
apacity.
d Cold Pressor-Induced Changes in MBF
in insulin-resistant states. (A) Summary of adenosine- or dipyridamole-stimu-
reduction in total vasodilator capacity (A, MBF) only in patients with diabetes
sting in insulin-resistant patients. Adapted from Prior et al. (12). DM  diabetes
e tolerance; IR  normoglycemic insulin resistance; IS  insulin sensitivity.F, an
esting
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February 3, 2009:S3–8 Coronary Abnormalities in Insulin ResistanceAttenuated flow responses to sympathetic stimulation
ikely reflect decreases in NO bioavailability—due to dimin-
shed synthesis, accelerated inactivation, or both. Dimin-
shed NO bioavailability likely results from a defect in the
nsulin-signaling pathway downstream to the insulin recep-
or and includes phosphorylation of insulin receptor sub-
tance protein and activation of phosphatidylinositol
-kinase, leading to phosphorylation of endothelial nitric
xide synthase (eNOS) and NO production (1). Low
nsulin receptor substance levels found in IR likely interfere
ith normal signal transduction, leading to diminished NO
ynthesis. In the basal state, NO levels may be diminished
ithout affecting resting myocardial flow, as suggested by
ndings in young healthy volunteers in whom resting flow
emained unchanged after inhibition of eNOS with L-nitro-
rginine methyl ester (14).
Mechanisms accounting for the progressively worse cor-
nary circulatory functional abnormalities observed in more
evere states of IR remain unclear. They may be related to
n increased number of vascular stressors, including elevated
lasma levels of free fatty acids, triglycerides, oxidized
ow-density lipoprotein cholesterol, and oxidation-prone
mall dense low-density lipoproteins. Pro-inflammatory cy-
okines and inflammatory markers such as C-reactive pro-
ein and adipocyte-derived adipokines contribute to further
ecreases in production and inactivation of NO. Formation
f reactive oxygen species in hyperglycemia, together with
nactivation of protein kinase C, may further impair vascular
unction (15,16). The observation of higher hyperemic
yocardial flow in T2DM with adequate glycemic control
ompared with poor glycemic control, independent of IR by
yperinsulinemic-euglycemic clamping (17), underscores the
ominant role of hyperglycemia and hyperglycemia-related
eactive oxygen species in coronary vascular dysfunction.
It is not clear if functional vasomotor disturbances in
vert clinical diabetes also directly affect vascular smooth
uscle function. Decreases in total vasodilator capacity in
2DM suggest this possibility; however, comparable reduc-
ions in vasodilator capacity (30%) have been observed
fter eNOS inhibition with L-nitro-arginine methyl ester in
oung normal volunteers (14). This observation suggests
hat reductions in hyperemic blood flow in T2DM may
esult from severe reductions in bioavailability alone, possi-
ly related to additive effects of multiple stressors.
Structural vascular alterations may lead to further reduc-
ions of the vasodilator capacity in T2DM. As demon-
trated with stress-rest SPECT myocardial perfusion imag-
ng, the reductions may remain confined to myocardial
erritories supplied by coronary vessels with macrovascular
isease. The DIAD (Detection of Ischemia in Asymptom-
tic Diabetics) study of 1,123 patients with T2DM showed
hat in 522 patients randomly assigned to stress-rest
PECT myocardial perfusion imaging, almost one-quarter
n  113) had silent ischemia (18). Perfusion defects were
oted in 16% of patients, and adenosine stress-inducedschemic electrocardiographic abnormalities or left ventric- (lar dilation or dysfunction occurred in 6% of the patients
ith normal myocardial perfusion. Microvascular structural
lterations affect coronary circulatory function more uni-
ormly, judging from the homogenously reduced hyperemic
ow patterns observed in patients with T2DM and diabetic
etinopathy or coronary microangiopathy (19,20). Com-
ared with controls, hyperemic myocardial flow was reduced
y 28% in patients with T2DM and macrovascular coronary
isease, but was reduced by 57% in patients with T2DM
nd coronary microangiopathy (20). The presence of coro-
ary microangiopathy was demonstrated by an abnormal
lectrocardiography stress test in the presence of angio-
raphically patent coronary vessels.
Endothelial dysfunction, even in the absence of macrovas-
ular coronary artery lesions, may be responsible for reduction
n or failure to appropriately augment coronary flow, leading to
yocardial ischemia (21). When coexisting with obstructive
oronary artery disease, endothelial dysfunction may cause
ore severe and extensive stress-induced perfusion abnormal-
ties (22), possibly because of stress-related sympathetically
ediated vasoconstriction (23).
Neuronal alterations in patients with diabetes account for
dditional reductions in the total vasodilator capacity and
or more severely reduced flow responses to CPT. Diabetic
europathy with sympathetic denervation of the left ven-
ricular myocardium, as demonstrated by PET imaging of
orepinephrine analog C-11 hydroxyephedrine uptake, has
een associated with further reductions in endothelium-
ependent flow responses (24,25).
Circulating insulin levels also have important effects on
yocardial flow at rest and during pharmacologically
timulated myocardial hyperemia. Infusion of insulin in
ealthy subjects and in patients with diabetes raises
yocardial flow at rest (26,27). Importantly, acute insulin
nfusion also evokes significant flow increases in patients with
oronary artery disease and T2DM (28). Euglycemic-
yperinsulinemic clamping raised plasma insulin levels more
han 7-fold and lowered glucose levels by 31%. With
erfusion imaging, resting myocardial flow increased13%,
hile adenosine-stimulated flow increased 23% in both
emote myocardium and regions with stress-induced flow
efects (Fig. 2) (28).
besity and Coronary Circulatory Function
besity is associated with an increased risk of coronary
therosclerosis and CV mortality and is an independent
oronary heart disease risk factor. Endothelial dysfunction
as been demonstrated in both the peripheral circulation,
ith forearm blood flow measurements, and in the coronary
irculation in obese patients with angiographically normal
r only mildly diseased coronary vessels (4,29–31). Endo-
helial dysfunction, independently associated with obesity,
ecame progressively worse with increased body weight
31). Endothelial dysfunction was confined to the coronary
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Coronary Abnormalities in Insulin Resistance February 3, 2009:S3–8esistance vessels without involving the large epicardial
onduit vessels. Because of the coexistence of elevated
asting glucose and triglyceride levels, as components of the
etabolic syndrome, IR was considered a possible cause of
ndothelial dysfunction. More recent observations with
ET-based measurements of myocardial flow revealed sim-
lar functional alterations of the coronary circulation in
bese persons (32). In this study, endothelium-dependent
oronary vasomotor function progressively declined with
ncreased body mass index (BMI) (Fig. 3) (32). Total
Figure 2 Effects of Insulin Infusion on MBF
Effects of insulin infusion on regional myocardial blood flow (MBF) at rest and
with adenosine-stimulated hyperemia in patients with type 2 diabetes mellitus
and coronary artery disease. Hyperinsulinemia significantly increased resting
and adenosine-stimulated blood flow in ischemic (gray bars) and nonischemic
(blue bars) myocardial regions. Adapted from Lautamäki et al. (28), with per-
mission from the American Diabetes Association.
Figure 3 MBF Responses of Normal Weight, Overweight, and O
Coronary vasomotor abnormalities are apparent in overweight (OW) persons (body
as myocardial blood flow (MBF) responses to cold pressor testing (CPT) and dipyri
Note that hyperemic blood flows are significantly reduced only in the obese patien
patients. Adapted from Schindler et al. (32). NS  not significant.asodilator capacity remained intact in overweight persons
BMI 25 and 30 kg/m2) but was significantly dimin-
shed in obese persons (BMI 30 kg/m2). On multivariate
nalysis, age and BMI were the only predictors of the
ttenuated flow response to CPT and, therefore, of endo-
helial dysfunction. While the reasons for this relation to
ge remain uncertain, they may be related to IR in the
resence of long-term obesity. These data may mechanisti-
ally link obesity with increased CV morbidity and mortality.
ndothelial Function, Coronary Risk,
nd Therapeutic Interventions
ultiple studies support an association between endothelial
ysfunction and increased coronary risk (33–36). Attenu-
ted or absent PET flow responses to CPT in patients with
ngiographically normal coronary vessels were associated
ith a 32% incidence of coronary events (cardiac death,
onfatal myocardial infraction, acute coronary syndromes,
evascularization, and stroke) over 66 months compared
ith a 4.5% incidence with normal flow responses (35).
Strategies that CV specialists may employ to improve
ndothelium-dependent coronary vasomotion include risk
actor modification and pharmacological approaches. In-
ense risk factor modification for 6 weeks (weight loss,
xercise, dietary lipid lowering) was accompanied by a 9%
mprovement in total vasodilator capacity (37). Insulin-
ensitizer treatment with a peroxisome proliferator-
ctivated receptor- agonist also led to improvements in
ow-mediated vasodilator responses in patients with
2DM as well as in endothelium-dependent coronary
asomotion in patients with impaired glucose tolerance
index [BMI] 25 and 30 kg/m2) and obese (OB) persons (BMI 30 kg/m2),
-stimulated hyperemic MBF are attenuated versus normal weight (NL) persons.
reas the flow response (MBF) to CPT is already attenuated in overweightbese
mass
damole
ts, whe
o
p
t
i
D
g
i
e
e
c
(
r
b
s
a
w
I
t
p
i
h
t
o
w
c
m
h
C
I
c
p
d
v
d
i
i
t
m
(
c
(
t
w
A
T
s
R
b
B
h
R
1
1
1
1
1
1
1
1
1
1
2
2
S7JACC Vol. 53, No. 5, Suppl S, 2009 Schelbert
February 3, 2009:S3–8 Coronary Abnormalities in Insulin Resistancer diabetes (38 – 41). Administration of peroxisome
roliferator-activated receptor- ligands (rosiglitazone or
roglitazone) for 12 weeks improved IR, lowered circulating
nsulin levels, and restored flow responses to CPT (40).
ietary and metformin-mediated reductions in circulating
lucose levels in patients with T2DM were associated with
mprovements in flow responses to CPT indicative of better
ndothelial function (42).
Whether pharmacologically mediated improvements in
ndothelium-dependent vasomotor function of the coronary
irculation reduce long-term CV risk remains uncertain
33). Indeed, the role of peroxisome proliferator-activated
eceptor- ligands in long-term reduction of cardiac mor-
idity and mortality remains controversial (43,44). In a
tudy of acute coronary syndrome patients, indices of
bnormal vasodilator function by forearm plethysmography
ere predictive of disease progression and CV events (45).
mportantly, recovery of endothelium-dependent vasodila-
or function 8 weeks after the index event was highly
redictive of subsequent event-free survival. Another study
n pre-menopausal women with mild-to-moderate arterial
ypertension and impaired brachial artery reactivity showed
hat improvements in flow-mediated dilation after 6 months
f aggressive antihypertensive treatment were associated
ith reduced incidence of CV events over 67 months
ompared with women without such functional improve-
ent (46). However, these findings should be considered
ypothesis generating.
onclusions
R is associated with important functional disturbances of the
oronary circulation. The magnitude of these disturbances is
roportional to the severity of the IR; in the case of pre-
iabetes, IR primarily affects the endothelium-dependent
asomotor function, whereas overt T2DM is associated with
iminished total vasodilator capacity. Administration of
nsulin to modify glycemic control can lead to substantial
mprovements in total coronary vasodilator capacity, even in
he presence of T2DM and coronary artery disease. Nor-
alization of endothelium-related functional abnormalities
which are considered to be independent predictors of
oronary risk) is possible with risk-modification treatment
diet and exercise) and insulin-sensitizing agents, although
he long-term effects of these agents on CV risk in patients
ith IR remain to be determined.
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